Table 2.
Multivariate analysis of intracranial progression‐free survival in patients with epidermal growth factor receptor (EGFR)‐mutated lung adenocarcinoma and brain metastases (BM) treated with EGFR–tyrosine kinase inhibitor (TKI) alone or with whole‐brain radiotherapy (WBRT), according to the Cox regression model
| B | SE | P‐value | OR | 95% CI | ||
|---|---|---|---|---|---|---|
| Lower | Upper | |||||
| Sex, male/female | −0.229 | 0.438 | 0.600 | 0.795 | 0.337 | 1.874 |
| Age, <65/≥65 years old | 0.187 | 0.368 | 0.611 | 1.206 | 0.587 | 2.478 |
| Tumor location, left/right lung | −0.050 | 0.268 | 0.853 | 0.952 | 0.563 | 1.609 |
| EGFR mutation status, Del‐19/L858R | −0.324 | 0.243 | 0.182 | 0.723 | 0.450 | 1.164 |
| Smoking status, never/former | −0.435 | 0.484 | 0.369 | 0.647 | 0.251 | 1.672 |
| BM number, ≤3/>3 | 0.538 | 0.291 | 0.064 | 1.713 | 0.968 | 3.030 |
| Intracranial symptoms, without/with | 0.013 | 0.263 | 0.959 | 1.014 | 0.605 | 1.698 |
| Treatment strategy, TKI alone/WBRT | −0.812 | 0.282 | 0.004 | 0.444 | 0.255 | 0.772 |
B, regression coefficient; CI, confidence interval; OR, odds ratio; SE, standard error.